Insight

Purification Challenges and Countermeasures for Complex Antibody Molecules

Bispecific and trispecific antibodies feature intricate structures and poor conformational stability. Their downstream purification processes must shift from the conventional platform-based strategy to highly customized solutions tailored to individual molecular properties. This article systematically elaborates on key challenges and corresponding mitigation strategies across six core unit operations: cell culture harvest, affinity capture, viral inactivation, polishing, viral filtration and ultrafiltration/diafiltration (UFDF).

1. Cell Culture Harvest & Clarification

Key Challenges

Complex antibodies generally exhibit lower expression titers, accompanied by elevated levels of cell debris, host cell proteins (HCP), host cell DNA and lipids. Many bispecific and trispecific antibodies contain hydrophobic single-chain variable fragments (scFv) or exposed hydrophobic patches, which readily bind to cell debris via non-specific interactions. This causes severe filter clogging during depth filtration and drastically reduces throughput compared with conventional monoclonal antibodies (mAbs). Additionally, these molecules are shear-sensitive, and tend to aggregate or degrade under centrifugation and pumping shear forces.

Solutions

Combined depth filtration: Adopt multi-stage depth filtration (3–5 μm pre-filter followed by 0.5–0.8 μm polish filter). Use filters with positively charged media layers (e.g., Millipore Millistak+ HC Pro, Sartorius Sartoclear) to remove DNA and partial HCP through electrostatic adsorption, alleviating the burden on subsequent chromatographic steps.

Flocculation pre-treatment: Add cationic polymers such as poly(diallyldimethylammonium chloride) or chitosan prior to harvest to aggregate cell debris and colloidal contaminants, which significantly increases the loading capacity of depth filters. Residual flocculants require rigorous validation.

Continuous harvesting technology: For highly unstable molecules, integrate perfusion culture with continuous disc stack centrifuges (e.g., GEA, Alfa Laval) inline with depth filtration. This shortens the residence time of feedstock in harvest tanks and minimizes shear-induced aggregation.

2. Affinity Capture

Key Challenges

Protein A affinity chromatography, the mainstream platform for conventional mAbs, faces three major limitations for complex antibodies. First, Fc region engineering (e.g., knob-into-hole mutations, FcγR binding site ablation) in many bispecific/trispecific antibodies markedly weakens or even abolishes Protein A binding. Second, molecules without Fc domains (e.g., tandem full-scFv constructs) are completely incompatible with Protein A resins. Third, even for bindable variants, harsh low-pH elution (pH 3.0–3.5) frequently triggers severe aggregation, precipitation or domain dissociation, leading to product recovery below 50%.

Solutions

Alternative affinity media: For molecules containing kappa light chains, select Protein L or KappaSelect resins targeting light chain variable or constant regions. Elution is performed at near-physiological pH to avoid low-pH stress. For tagged molecules, immobilized metal affinity chromatography (IMAC) or antigen affinity chromatography is applicable.

Alkali-stable resins and mild elution conditions: If Protein A is mandatory, employ alkali-resistant high-capacity resins (e.g., MabSelect PrismA). Implement gradual pH gradient elution (pH 5.0 down to 3.8) instead of abrupt pH shift. Supplement elution buffers with 0.3–0.5 M arginine, 5–10% propylene glycol or 0.02% polysorbate 80 to stabilize molecular conformation and suppress aggregation.

Flow-through cation exchange capture: For molecules with high isoelectric points (pI), adopt cation exchange chromatography in flow-through mode. This approach features mild operating conditions and lower overall costs, despite slightly reduced binding capacity.

3. Viral Inactivation

Key Challenges

Low-pH incubation (pH 3.5–3.8, 60–90 min at ambient temperature) and detergent treatment (TNBP/Triton X-100) are standard viral inactivation methods. Low-pH exposure poses the primary risk for complex antibodies. These molecules are prone to reversible or irreversible aggregation, mispair rearrangement and degradation under acidic conditions, compromising product purity and yield. Improper neutralization may also cause local pH surge and subsequent precipitation.

Solutions

Optimized low-pH protocols: Conduct stability screening to determine the minimum tolerable pH and shortest safe exposure duration for each molecule. High-throughput screening and microfluidic platforms can rapidly identify critical stability thresholds. For acid-labile molecules, raise the inactivation pH to 4.0–4.2 and extend incubation time to 120 min, which still achieves ≥4 log viral reduction.

Stabilizer supplementation: Add 0.1–0.2 M trehalose, sorbitol or arginine to eluates prior to viral inactivation. These polyols stabilize protein conformation via preferential hydration and effectively mitigate aggregation.

Alternative inactivation approaches: For extremely acid-sensitive molecules, apply detergent-based inactivation (1% Triton X-100 + 0.3% TNBP, 30 min), nanomaterial-based or UV viral inactivation. Residual detergents must be thoroughly removed via polishing chromatography or UFDF with corresponding residual validation.

4. Polishing

Conventional polishing workflows typically consist of two chromatographic steps (ion exchange combined with hydrophobic interaction or mixed-mode chromatography) to remove process- and product-related impurities. For complex antibodies, the primary targets include product-related variants (mispaired species, homodimers, half-antibodies and fragments) and process-related contaminants (aggregates, residual Protein A, HCP and DNA).

Key Challenges

Difficult separation of mispaired species: Mispaired variants have molecular weights nearly identical to the target product, with minimal pI differences (ΔpI < 0.2), resulting in insufficient resolution of conventional cation exchange chromatography.

Aggregate formation: High-load sample loading and buffer exchange during polishing easily re-induce aggregation. Aggregates and monomers exhibit marginal differences in surface hydrophobicity and net charge, further hindering separation.

Solutions

Mixed-mode chromatography (MMC): A core tool for polishing complex antibodies. Anion-exchange/hydrophobic mixed-mode resins (e.g., Capto Adhere) operated in flow-through mode at pH 5.0–6.0 efficiently remove aggregates, HCP and residual Protein A while retaining high product recovery and purity. Cation-exchange/hydrophobic mixed-mode resins (e.g., Capto MMC) are used in bind-elute mode to separate mispaired species based on subtle hydrophobic differences.

Hydroxyapatite chromatography: Leverage interactions between calcium ions and phosphate groups to resolve phosphorylated variants, conformational isomers and aggregates. It shows unique performance in removing recalcitrant impurities that cannot be separated by ion exchange or hydrophobic chromatography.

High-resolution polishing chromatography: Use fine-particle ion exchange resins (e.g., Source 15Q, Source 15S). Optimize loading capacity and elution buffer compositions to achieve baseline separation between target molecules and mispaired variants.

5. Viral Filtration

Key Challenges

Viral nanofiltration using 20 nm membranes (e.g., Planova 20N, Viresolve Pro) serves as a critical physical barrier for viral safety. Complex antibodies with asymmetric architectures (e.g., tandem scFv, flexible linkers) are easily trapped within membrane pores, leading to severe throughput decline. Trace aggregates in feedstock will cause membrane fouling and filtration failure. Moreover, these molecules are pressure-sensitive, and excessive transmembrane pressure generates shear force and triggers aggregation.

Solutions

Pre-filtration and membrane selection: Install 0.1 μm or dual-layer pre-filters upstream to remove submicron particulates. Select hydrophilic modified polyethersulfone (PES) membranes with low protein adsorption. Asymmetric membranes with three-dimensional network structures are preferred for flexible molecules over track-etched membranes.

Process parameter optimization: Run filtration under constant pressure rather than constant flow, and control transmembrane pressure below 20–25 psi. Add 0.005%–0.01% polysorbate 80 to feedstock to reduce hydrophobic interactions between molecules and membrane surfaces, improving throughput and loading capacity.

6. Ultrafiltration/Diafiltration (UFDF)

Key Challenges

UFDF is the final unit operation to concentrate proteins to target concentrations (typically >50 mg/mL) and perform buffer exchange for formulation. It represents the highest-risk stage for bispecific and trispecific antibodies:

High-concentration aggregation: Local protein concentration can reach hundreds of mg/mL during concentration, driving intermolecular hydrophobic interactions and domain rearrangement to form aggregates.

Shear sensitivity: Recirculation pumps in tangential flow filtration (TFF) generate shear force, which induces conformational changes, degradation and subvisible particle formation.

Yield loss: More severe non-specific adsorption on membrane surfaces and concentration polarization occur compared with conventional mAbs, resulting in reduced recovery.

Solutions

Membrane material and molecular weight cutoff (MWCO) selection: Adopt low-adsorption modified PES or regenerated cellulose membranes. Select 30 kDa MWCO for full-length molecules and 50 kDa MWCO for molecules with large domains to enhance throughput and minimize gel layer formation.

Stabilizer addition: Supplement UFDF buffers with stabilizers. A combination of 0.1–0.2 M arginine and 0.2 M sucrose/trehalose is widely applied to inhibit intermolecular interactions and high-concentration aggregation.

Process parameter control: Operate under constant flux mode, with shear rate controlled below 2000 s⁻¹ and transmembrane pressure below 20 psi. Apply gradual diafiltration instead of rapid one-step buffer exchange to avoid osmotic shock and transient high-concentration aggregation. For highly sensitive molecules, adopt single-pass tangential flow filtration (SPTFF) to separate concentration and diafiltration steps, reducing recirculation duration and shear exposure.

Final concentration strategy: For target concentrations above 100 mg/mL, perform final concentration after diafiltration. Use low-shear pumps and gentle stirring to prevent irreversible aggregation caused by extreme local concentration at the late stage.

Conclusion

Purification of bispecific, trispecific and other complex antibodies has gone beyond the scope of traditional mAb platform processes. The core principle relies on in-depth characterization of molecular properties and integrated full-process design. Starting from cell culture harvest, flocculation or continuous processing is applied to protect molecules from shear damage. Flexible selection of alternative affinity media and mild elution strategies are implemented in affinity capture. Stabilizers and alternative inactivation methods are adopted to mitigate low-pH risks during viral inactivation. Mixed-mode chromatography and hydroxyapatite resins act as powerful tools to resolve subtle variants in polishing. Rigorous aggregate control and optimized membrane parameters are required for viral filtration. Finally, additives and precise hydrodynamic control in UFDF guarantee molecular stability and high recovery at high protein concentrations.

The entire workflow is no longer a simple series of unit operations, but requires close collaboration between upstream and downstream processes. Upstream cell line engineering can optimize molecular stability and secretion performance, while downstream processes deploy targeted protective strategies against molecular vulnerabilities. Systematic and molecule-specific process development enables efficient manufacturing of complex antibody drugs with guaranteed high purity and viral safety.

Insight

Purification Challenges and Countermeasures for Complex Antibody Molecules

INQUIRY NOW

Inquiry Now